Graft Versus Host Disease Therapeutics
1. Imbruvica patent expiration
Treatment: Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of adult patients with relapsed or refractory chronic lym...
IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296753 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(7 years from now) | |
| US9181257 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US8957079 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US8735403 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US7514444 | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US10125140 | PHARMACYCLICS | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10106548 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9725455 | PHARMACYCLICS | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US8008309 | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(1 year, 8 months from now) | |
| US8697711 | PHARMACYCLICS | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8563563 (Pediatric) | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(1 year, 8 months from now) | |
| US9814721 | PHARMACYCLICS | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US10653696 | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US8999999 | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
| US10004746 | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10016435 | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9801881 | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US9801883 | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9125889 | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8476284 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US8754090 | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10463668 | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US10695350 | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US8563563 | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(1 year, 2 months from now) | |
| US8703780 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US8952015 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US11672803 | PHARMACYCLICS | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8497277 | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US10478439 | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10751342 | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9795604 | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US12364698 | PHARMACYCLICS | Compositions Containing Ibrutinib |
Apr, 2036
(10 years from now) | |
| US8754091 | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(10 months from now) | |
| US10961251 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10010507 | PHARMACYCLICS | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
| US10213386 | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10752634 | PHARMACYCLICS | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9713617 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10294231 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9540382 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(7 years from now) | |
| US10294232 | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9655857 | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10828259 | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US12201690 | PHARMACYCLICS | Formulations/compositions comprising ibrutinib |
Jun, 2039
(13 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
May, 2028
(2 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(8 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 4 months from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(7 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 13 November, 2017
Market Authorisation Date: 16 February, 2018
Dosage: TABLET; CAPSULE; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
2. Jakafi patent expiration
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-ess...
JAKAFI's oppositions filed in EPO
JAKAFI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9662335 | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(9 months from now) | |
| US8722693 | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US8415362 | INCYTE | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(1 year, 10 months from now) | |
| US7598257 | INCYTE | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822481 | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US10016429 | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US9814722 | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(9 months from now) | |
| US9079912 | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(9 months from now) | |
| US8829013 | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
|
US7598257 (Pediatric) | INCYTE | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US8415362 (Pediatric) | INCYTE | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US8722693 (Pediatric) | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8822481 (Pediatric) | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8829013 (Pediatric) | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US9079912 (Pediatric) | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(1 year, 3 months from now) | |
|
US9814722 (Pediatric) | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(1 year, 3 months from now) | |
|
US10016429 (Pediatric) | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 17 November, 2015
Market Authorisation Date: 16 November, 2011
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
3. Rezurock patent
expiration
Treatment: Treatment of chronic graft-versus-host disease (chronic gvhd) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 12 years and older with a grade 3 infection ...
REZUROCK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON | Pharmacokinetically improved compounds |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12097202 | KADMON | Methods of administering Belumosudil for treatment of chronic graft versus host disease |
Jul, 2042
(16 years from now) | |
| US11311541 | KADMON | Treatment of GVHD |
Apr, 2035
(9 years from now) | |
| US10696660 | KADMON | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| US10183931 | KADMON | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| US9815820 | KADMON | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Dosage: TABLET
How can I launch a generic of REZUROCK before it's drug patent expiration?
More Information on Dosage
REZUROCK family patents